ZYBERNO
Stock Report
Updated Aug 23, 2026

Biodexa Pharmaceuticals PLC (BDRX)

Healthcare • NASDAQ

$1.27

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
14.0/100
POOR BUSINESS
Biodexa Pharmaceuticals PLC (BDRX) scores 14/100 — concerning metrics indicating significant structural or financial risks.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (0.0%)
Debt-to-Equity (Solvency Risk):EXCELLENT (0.02x)
Operating Margin (Operational Efficiency):CRITICAL (0.0%)
Return on Capital (Capital Efficiency):CRITICAL (-190.6%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

Biodexa Pharmaceuticals PLC (BDRX) stock report — Zyberno Score 14/100 (POOR BUSINESS). Full financial analysis on Zyberno.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:1.27
Market Cap:$5.89B

Valuation Multiples (3)

P/B Ratio:382.94x
P/S Ratio:11,462.98x
Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:$5.88B

Price Action & Momentum (1)

% of 52-Week High:2.1%
B. Profitability Assessment

Return Metrics (3)

Reinvestment Rate:1.8%
Fundamental Growth Rate (g):-3.4%

Margin Analysis (1)

Ebitda Margin:-2,068.5%

Yield Metrics (2)

Earnings Yield:-$999.00
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:2.03x
Quick Ratio:1.88x
Cash Ratio:1.39x

Leverage Analysis (3)

Debt To Equity Ttm:0.02x
Debt-to-Equity Ratio:0.02x
Debt To Ebitda:-999.00x

Coverage Ratios (2)

Interest Coverage Ratio:-35.00x
Times Interest Earned:-35.00

Capital Structure (4)

Working Capital:8,510,495.38
Cash And Cash Equivalents:11,502,782.32
Long Term Debt:$159.05K
Net Debt:-$11.12M
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

$513.54K
Cost Of Revenue Ttm:$1.25M

Profitability Breakdown (2)

-$734.59K-$10.80M

Bottom Line Performance (3)

-$9.54M
Income Before Tax:$0.00
Ebitda Ttm:-10,622,618.64

Operating Expenses (5)

Operating Expenses:0.00
R And D Expense:0.00
Sga Expense:0.00
Income Tax Expense:-$141.53K
Interest Expense:308,663.83

Expense Ratios (3)

R And D To Revenue Percentage:0.0%
Sga To Revenue Percentage:0.0%
Ebitda Margin:-2,068.5%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$24.50M
Current Assets:$16.77M
Ppe Net:122,656.81
Goodwill:0.00
Intangible Assets:$7.61M

Liability Structure (4)

Total Liabilities:9,130,518.80
Current Liabilities:8,261,138.13
Long Term Debt:$159.05K
Short Term Debt:$221.05K

Equity & Capital (3)

Equity:$15.37M
Retained Earnings:$0.00
Common Stock:0.00

Working Capital Items (3)

Accounts Receivable:5,103,062.32
Inventory:1,268,352.26
Accounts Payable:3,491,001.43

Special Items (2)

Contract Liabilities:0.00
Stock Based Compensation:0.00
C. Cash Flow Analysis

Operating Activities (2)

-$9.20M-$7.54M

Investment Activities (1)

Investing Cash Flow:-$785.81K

Financing Activities (3)

Financing Cash Flow:$17.57M
Dividends Paid Ttm:0.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:0.00
Long Term Debt Issuance:$0.00
Long Term Debt Repayments:$0.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (1)

Earnings Per Share Ttm:-$0.00

Revenue & Cash Per Share (2)

Sales Per Share Ttm:0.00
Operating Cash Flow Per Share:-$0.00

Book Value & Capital (2)

Book Value Per Share:$0.00
Cash Per Share:0.00

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (2)

Asset Turnover Ttm:0.02x
Working Capital Turnover Ttm:0.06x

Receivables Management (2)

Receivables Turnover Ttm:0.10x
Days Sales Outstanding Ttm:3,627.01

Inventory Management (2)

Inventory Turnover Ttm:0.98x
Days Inventory Outstanding Ttm:370.91

Payables & Cash Cycle (2)

Days Payable Outstanding:1,020.90
Cash Conversion Cycle:2,977.02
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:100.00
Quality Score:40.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Damodaran Growth Analysis (2)

Reinvestment Rate:1.8%
Fundamental Growth Rate (g):-3.4%
B. Log-Linear Regression Growth Analysis
C. Company Profile & Context

Corporate Information (6)

Symbol:BDRX
Company Name:Biodexa Pharmaceuticals PLC
Sector:Healthcare
Industry:Pharmaceuticals
Exchange:NASDAQ
Country:United States

Market Classification (3)

Market Cap Category:N/A
Price Category:low
Volume Category:N/A

Share Structure (3)

Shares Outstanding:4.64B
Shares Outstanding Basic:0
Shares Outstanding Diluted:0

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-08-23 11:44:20 UTC
Data Timestamp:2026-08-22T12:13:25.259207
Scroll to Top